A Delaware federal judge has ruled four patents held by Teva Pharmaceuticals invalid as obvious, potentially clearing a path for competitors to bring generic versions of the company’s multiple sclerosis drug to market.
The ruling, announced late Monday, calls into question the future of the Israeli pharmaceutical giant’s 40-milligram injectable dose of Copaxone, the company’s top-selling drug, and it represented a clear win for Mylan Pharmaceuticals, Amneal Pharmaceuticals and three other drugmakers that have applied to market generic alternatives.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
